In colorectal cancer (CRC), cetuximab use is guided by the presence of RAS mutations (23), with KRAS alterations being a robust predictor of both adverse prognosis and cetuximab resistance (24, 25). This evidence concerns the gene KRAS and colorectal carcinoma.